Congenital Hyperinsulinism Market to Expand at a CAGR of 12% During the Forecast Period (2026-2036) as Rising Disease Recognition and Novel Therapies Fuel Market Growth | DelveInsight

DelveInsight estimates the congenital hyperinsulinism market at USD 110 million in the 7MM in 2025 (CAGR 12%), with diagnosed prevalent cases at 15,700 in 2025 expected to rise through 2036. The article highlights a shift from inadequate symptom-control therapies (e.g., diazoxide; somatostatin analogs) toward targeted pipeline drugs including Dasiglucagon, Ersodetug (Phase III; primary endpoint missed in sunRIZE), Avexitide, and Efpegerglucagon, which could reshape standards of care. Overall, the outlook is constructive due to expanding diagnosis and a growing—though still early—novel-therapy pipeline.

Analysis

This is not a broad sector catalyst; it is a reminder that CHI is a classic orphan-optionalities market where commercial value is driven more by label quality, convenience, and diagnosis funnel expansion than by headline TAM. The real winner profile is a company that can convert a rare pediatric endocrine niche into a durable specialist-center franchise with low COGS and high pricing power; that favors therapies that are easier to administer and scale than chronic hospital-heavy protocols. For the larger healthcare names in the data set, the direct P&L impact is negligible.

The more actionable read-through is competitive. A prior Phase III miss leaves RZLT exposed to funding and dilution risk if it has to keep pushing a program with reduced credibility, while any positive readout from ZLDPF or AMLX would re-rate them on probability-adjusted peak sales rather than current revenue. Second-order, if diagnostics improve faster than expected, the first companies to benefit will be those already set up in rare-disease specialty channels; if not, the forecasted growth can lag because underdiagnosis is the real bottleneck, not lack of drug choice.

Timing matters: over the next 1-3 months this is mostly a sentiment item, but the 6-18 month catalyst path is binary around regulatory resubmission and late-stage data. The contrarian view is that the market may be overpricing the steadiness of the growth curve; in ultra-small orphan markets, one endpoint miss or one reimbursement issue can cut the commercial opportunity in half. What would falsify a bearish stance on RZLT is convincing partner support or new efficacy data; what would falsify the bullish orphan optionality thesis is weak access, slow diagnosis uptake, or a lack of durable safety differentiation versus glucagon-based approaches.

Key Decisions for Investors

• Keep broad mega-cap pharma names (LLY, NVO, NVS, BAX, TEVA) on no-trade status here; the CHI opportunity is too small to move group fundamentals in the next 12 months.
• Small long bias in ZLDPF into the H2 2026 resubmission window, but only as a catalyst trade: upside comes from probability re-rating, not revenue scale; stop if filing timing slips materially.
• Fade RZLT strength / maintain short or underweight into any rallies until there is proof of durable efficacy after the prior Phase III miss; the main risk is capital structure pressure if execution drags.
• Watch AMLX as a binary event-driven long only on data confirmation, not on this market report; if H2 2026 topline is positive, the stock can re-rate faster than the market size would suggest because orphan models trade on peak penetration assumptions.